Pheton (NASDAQ:PTHL – Get Free Report) and Establishment Labs (NASDAQ:ESTA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
Profitability
This table compares Pheton and Establishment Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pheton | N/A | N/A | N/A |
| Establishment Labs | -24.19% | -201.79% | -15.03% |
Institutional and Insider Ownership
72.9% of Establishment Labs shares are held by institutional investors. 11.1% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pheton | $305,215.00 | 8.49 | -$660,000.00 | N/A | N/A |
| Establishment Labs | $211.08 million | 7.68 | -$51.06 million | ($1.74) | -31.79 |
Pheton has higher earnings, but lower revenue than Establishment Labs.
Analyst Ratings
This is a summary of current ratings and price targets for Pheton and Establishment Labs, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pheton | 1 | 0 | 0 | 0 | 1.00 |
| Establishment Labs | 1 | 1 | 6 | 0 | 2.63 |
Establishment Labs has a consensus price target of $86.86, suggesting a potential upside of 57.04%. Given Establishment Labs’ stronger consensus rating and higher probable upside, analysts plainly believe Establishment Labs is more favorable than Pheton.
Volatility and Risk
Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
About Pheton
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Receive News & Ratings for Pheton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pheton and related companies with MarketBeat.com's FREE daily email newsletter.
